Cutting Edge Biotech Companies Human Genome Sciences (HGSI) and Dendreon Corp. (DNDN) Are Poised To Go Higher

Planning to invest in the biotech sector? Louis Navallier says to look for companies like Human Genome Sciences (NASDAQ: HGSI) and Dendreon Corp. (NASDAQ: DNDN) that are on the cutting-edge of innovation, research and developing treatments for major diseases.

After HGSI's drug for Lupus, Benlysta, showed good results in a late stage clinical trial, its stock prices went up. The company partnered with pharmaceutical giant GlaxoSmithKline (NYSE: GSK) to cover the testing expenses. Human Genome's drug for Lupus - a painful disease that occurs when the body's immune system attacks its own healthy tissues - has not been approved in 50 years, and this kind of medication has tremendous revenue potential. Its shares upgraded by almost 50% recently, and Louis Navallier suggests you buy it before it gets any higher, which it very probably will.

Dendreon Corp., whose main product is Provenge, a vaccine for the treatment of prostate cancer, is another important up and coming biotech firm. Dendreon just submitted its drug to the FDA for approval, and it is approved, it will be the only drug of its kind that is available in the US. You can imagine the revenue potential.